Key statistics
On Saturday, Arrowhead Pharmaceuticals Inc (A2RR34:SAO) closed at 41.40, -17.73% below its 52-week high of 50.32, set on Jan 06, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 39.64 |
|---|---|
| High | 41.52 |
| Low | 39.64 |
| Bid | 39.24 |
| Offer | 41.64 |
| Previous close | 41.01 |
| Average volume | 614.60 |
|---|---|
| Shares outstanding | -- |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | -- |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Feb 14 2026 00:45 GMT.
More ▼
Press releases
- Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
- Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
- Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
- Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
- Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
- Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
More ▼
